106 related articles for article (PubMed ID: 23592289)
1. [Prostate cancer: radiotherapy or operation?].
Aktuelle Urol; 2013 Mar; 44(2):103-4. PubMed ID: 23592289
[No Abstract] [Full Text] [Related]
2. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective.
Crook J; Esche B; Futter N
Urology; 1996 Mar; 47(3):387-94. PubMed ID: 8633407
[TBL] [Abstract][Full Text] [Related]
3. [Prostate cancer: large PREFERE Study evaluates therapies].
Aktuelle Urol; 2013 Mar; 44(2):105. PubMed ID: 23592290
[No Abstract] [Full Text] [Related]
4. Prostate cancer: biological dose considerations and constraints in tele- and brachytherapy.
Dörr W; Jaal J; Zips D
Strahlenther Onkol; 2007 Dec; 183 Spec No 2():14-5. PubMed ID: 18166999
[No Abstract] [Full Text] [Related]
5. Erectile dysfunction after radiotherapy for prostate cancer.
Mendenhall WM; Henderson RH; Indelicato DJ; Keole SR; Mendenhall NP
Am J Clin Oncol; 2009 Aug; 32(4):443-7. PubMed ID: 19657239
[TBL] [Abstract][Full Text] [Related]
6. [Quality of life after radiotherapy for prostate cancer].
Joly F; Degrendel AC; Guizard AV
Cancer Radiother; 2010 Oct; 14(6-7):519-25. PubMed ID: 20728393
[TBL] [Abstract][Full Text] [Related]
7. [Dosimetric factors predictive of late toxicity in prostate cancer radiotherapy].
de Crevoisier R; Fiorino C; Dubray B
Cancer Radiother; 2010 Oct; 14(6-7):460-8. PubMed ID: 20797890
[TBL] [Abstract][Full Text] [Related]
8. Improved quality of life following radical radiation therapy for early stage carcinoma of the prostate.
Leibel SA; Pino y Torres JL; Order SE
Urol Clin North Am; 1980 Oct; 7(3):593-604. PubMed ID: 7456172
[No Abstract] [Full Text] [Related]
9. [Critical review of use of radiation as initial treatment for localized prostate cancer].
Esquena S; Sánchez-Martín FM; Palou Redorta J; Rosales Bordes A; Rodríguez-Faba O; Villavicencio Mavrich H
Actas Urol Esp; 2010 Jan; 34(1):6-9. PubMed ID: 20223126
[No Abstract] [Full Text] [Related]
10. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
Gore JL; Kwan L; Lee SP; Reiter RE; Litwin MS
J Natl Cancer Inst; 2009 Jun; 101(12):888-92. PubMed ID: 19509365
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of late side-effects of conformal and conventional radiotherapy in locally limited prostatic carcinoma. A prospective randomized study].
Feldmann HJ
Strahlenther Onkol; 1999 Jul; 175(7):350-1. PubMed ID: 10433000
[No Abstract] [Full Text] [Related]
12. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
Albertsen PC
J Urol; 2005 Nov; 174(5):1969-70. PubMed ID: 16217368
[No Abstract] [Full Text] [Related]
13. [Surveillance after prostate cancer radiotherapy].
Supiot S; Rio E; Clément-Colmou K; Bouchot O; Rigaud J
Cancer Radiother; 2011 Oct; 15(6-7):540-5. PubMed ID: 21795093
[TBL] [Abstract][Full Text] [Related]
14. Review: alcohol and other factors related to late prostate radiation injury.
Koontz BF; Vujaskovic Z
Clin Adv Hematol Oncol; 2009 Apr; 7(4):262. PubMed ID: 19521330
[No Abstract] [Full Text] [Related]
15. Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer.
D'Ambrosio DJ; Pollack A; Harris EE; Price RA; Verhey LJ; Roach M; Demanes DJ; Steinberg ML; Potters L; Wallner PE; Konski A
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):671-7. PubMed ID: 18262085
[No Abstract] [Full Text] [Related]
16. Treatment of early stage prostate cancer: radical prostatectomy.
Walsh PC; Partin AW
Important Adv Oncol; 1994; ():211-23. PubMed ID: 8206491
[No Abstract] [Full Text] [Related]
17. Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment.
Bhatnagar V; Stewart ST; Huynh V; Jorgensen G; Kaplan RM
Prostate Cancer Prostatic Dis; 2006; 9(2):136-46. PubMed ID: 16402091
[TBL] [Abstract][Full Text] [Related]
18. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
19. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
20. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
